Jelly Force Ingredients: The Nine Names on the Label

A root from the Brazilian Amazon, traded since the nineteenth century as marapuama or potency wood. It leads the panel and it is the weakest item on it by evidence: there is no controlled trial of muira puama in human beings in the indexed literature, for sexual function or for anything else. It reaches people only inside other products, in a one-month study of a ginkgo formula in women and a three-month pilot of a four-part mixture in men, neither with a placebo group and neither able to isolate the root.

What does exist is a body of rodent pharmacology from one Brazilian group. An extract inhibited acetylcholinesterase in mouse brain, and in a separate behavioural study the same kind of extract was anxiogenic rather than calming — which is the opposite of what a tonic is usually sold on, and is the reason it appears here. The root's chemistry has been properly catalogued, so this is a well-described plant with no human outcome attached to it.

A cruciferous relative of the radish, farmed on the Peruvian altiplano at an altitude where almost nothing else is, and eaten locally by the spoonful. It carries more controlled human evidence on sexual desire than anything else on this panel.

A twelve-week randomised trial in men aged 21 to 56 gave 1,500 mg or 3,000 mg a day and found self-reported sexual desire improved from week eight. The same trial measured serum testosterone and oestradiol in the same men and found neither changed, which is the single most useful sentence about maca anywhere: whatever it does, it does not do it by raising testosterone. A second trial gave 2,400 mg a day of dry extract to fifty men with mild erectile dysfunction and found a small but significant advantage over placebo on the IIEF-5 questionnaire. A third, in eighty men with late-onset hypogonadism symptoms, dosed three times a day for twelve weeks and improved symptom and erectile scores.

The systematic review of this field is fair about its limits: few trials, small samples, mostly self-reported outcomes. The doses, though, are consistent. Every one of them is measured in grams.

A Brazilian bark with one of the strongest folk reputations on the panel and no controlled human trial behind it. The name is also used commercially for at least two unrelated plants, so a label naming catuaba is naming a trade description rather than a species — this page uses Trichilia catigua because that is what the published pharmacology works on.

That pharmacology is real: antidepressant-like activity through dopaminergic mechanisms in rodents, and antioxidant, anticholinesterase and antifatigue effects in a later study. There is also a finding that no page selling this bottle has any business omitting: crude catuaba extract impaired fertility in adult female rats, though it did not damage the reproduction of male offspring. Jelly Force is sold to adult men, and the finding is in rats at doses unrelated to a gummy, so it is context rather than a warning. It is still the sort of context this desk would want to have been told.

Its only appearance in people is a twenty-eight-day safety study of Catuama, a Brazilian tonic mixing catuaba with muira puama, guarana and ginger. Healthy volunteers showed no severe reaction, and no benefit was measured.

The leaf of the tea plant, concentrated. It is on the panel and not in the seller's advertising, and the panel says nothing about what the extract is standardised to.

No trial of green tea extract on sexual function or stamina is cited on this website, because its literature is about other outcomes. What is cited is its safety record, because that record is specific: the US Pharmacopeia review of green tea extracts tied published liver-injury cases to intakes of the catechin EGCG from 140 mg to about 1,000 mg a day, and noted that concentrated doses taken on an empty stomach are absorbed the most.

The arithmetic here runs in the reassuring direction. The whole blend weighs 82 mg, the green tea extract is only part of it, and EGCG only part of the extract, so one gummy sits below the lowest intake in those reports.

Printed as its own entry, Caffeine (5mg), between green tea extract and ashwagandha — the one number in the blend that belongs to a single name. The panel does not say whether it comes from the tea or is added separately, and it is not in the advertising.

5 mg is small. MedlinePlus gives an 8-ounce cup of tea at 14 to 60 mg and a cup of coffee at 95 to 200 mg, and a systematic review of caffeine safety found intakes up to 400 mg a day were not associated with adverse effects in healthy adults, and 300 mg in pregnancy. One gummy is an eightieth of the adult figure.

It is named anyway, because a buyer who avoids caffeine for sleep, heart rhythm or anxiety should be told rather than left to find it on the back of the bottle. The figure also does a second job, set out in the callout above: it anchors where the other names sit by weight.

One of the best-studied names on the panel, and the one with the largest file of published safety signals. In men, the trial record is specific: 675 mg a day in three doses for ninety days raised sperm count, volume and motility in forty-six oligospermic men, and 300 mg twice a day for eight weeks improved questionnaire scores for sexual function in fifty men with lower desire. A meta-analysis pooled the fertility work.

The counterweight is in the same literature and matters more than most caveats. A 2026 scoping review collected twenty-five patients across thirteen publications with liver injury attributed to ashwagandha: typically after weeks of use, typically cholestatic, usually reversible on stopping, and in one case severe enough to require transplantation. Separately, thyroid over-activity has been reported. The NCCIH page and the LiverTox monograph both carry it. None of that makes ashwagandha dangerous for most people. It makes liver disease, thyroid disease and thyroid replacement specific reasons to ask first.

One trial is worth noting for its scale rather than its result. A crossover study in aging, overweight men used a concentrated extract delivering 21 mg of withanolide glycosides a day and found fatigue and vigour did not separate from placebo, though DHEA-S and testosterone did shift. It is the trial closest in scale to a blended gummy, and it is the one that found the least.

The one amino acid on the panel, and mechanically the most transparent thing on it. Arginine is the substrate for nitric oxide synthase; nitric oxide relaxes the smooth muscle in a vessel wall; that relaxation is what an erection is, physically. The prescription drugs in this category work on the same pathway one step further along.

A meta-analysis of ten randomised trials in 540 men with mild to moderate erectile dysfunction found arginine supplements improved outcomes against placebo at daily doses from 1,500 mg to 5,000 mg. Eleven blood-pressure trials in 387 people, at 4 to 24 grams a day, found systolic pressure fell 5.4 mmHg and diastolic 2.7 mmHg.

Both of those numbers cut two ways on this bottle. They are evidence that the ingredient does something, and they are the reason the interaction section of this site is specific rather than general: anything else that widens a vessel is additive with it.

A low, spiny plant of warm dry ground whose fruit and leaf are sold as a vitality herb. It is on the panel and not in the advertising, and it has the most mixed human record on the bottle.

A twelve-week trial in 180 men with mild or moderate erectile dysfunction gave 1,500 mg a day of a standardised extract and found erectile scores improved against placebo. A thirty-day trial in thirty men at 800 mg a day found no difference from placebo on erectile scores or total testosterone. A 2026 meta-analysis of eight studies found erectile scores favoured tribulus and testosterone did not differ.

The testosterone claim so often attached to tribulus does not survive its own literature: a systematic review concluded it is ineffective for raising testosterone in humans. There is a safety file too: severe liver and kidney injury after two months of daily supplements, and an earlier kidney case. All of it at amounts far above any share of an 82 mg blend.

Leaves of Epimedium, a genus of low woodland plants used in Chinese herbal medicine. Last on the panel and missing from the advertising. The panel names no species and no standardisation, and does not mention icariin, the compound most of the research is about.

What the record holds is laboratory work. Icariin inhibited PDE5 in test-tube work — the enzyme sildenafil and tadalafil block — at roughly three times the concentration of the reference inhibitor, and in another assay about eighty times more weakly than sildenafil. In castrated rats, oral icariin for four weeks improved erectile pressure while serum testosterone did not move. This desk found no trial of horny goat weed alone on sexual function in people.

Two case reports matter more to a buyer than the rat work: a racing heart rhythm with hypomania, and severe muscle spasms with raised creatine kinase after a month of a stand-alone supplement. And because its mechanism is the prescription tablets' mechanism, it joins arginine in the one interaction question on this bottle worth a telephone call.